Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
WAYNE, N.J., May 29 /PRNewswire/ -- Bayer Healthcare Pharmaceuticals Inc. today announced that several studies evaluating the use of Leukine(R) (sargramostim) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting.
"We are excited to see that several studi...
Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
EXTON, Pa., May 26 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY ) announced that its cartilage repair device has been highlighted in two podium presentations
at the 8th World Congress of the International Cartilage Repair Society (ICRS) Meeting held in Miami, FL on May 23-26, ...
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations
or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) A...
Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Safety and Efficacy Data from Phase 3 Study will be Highlighted
SAN DIEGO, May 7 /PRNewswire-USNewswire/ -- Chronic pain is a significant medical challenge in the United States, and chronic low back pain is the most common cause of disability in developed countries. An estimated 100 million A...
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting
SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of s...
Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
TAMPA, Fla., April 30 /PRNewswire/ -- Sirion Therapeutics, Inc. announced today that eight presentations
related to the Company's products, pipeline and research will be presented at the 2009 annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL.
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Final results from three large PEGINTRON(TM) clinical studies address key questions in the treatment of hepatitis C
COPENHAGEN, Denmark, April 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that final results of three large PEGINTRON(TM) (peginterferon ...
Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
Pivotal Trial Expected to Initiate in 2010 for Blinatumomab
NEW YORK, April 24 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today held an R&am...
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
MISSISSAUGA, ON, March 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported that its poster entitled, "Binding properties of the ant...
Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
RICHMOND, Calif., March 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business ...
Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
WAYNE, N.J., Dec. 5 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data on Campath(R) (alemtuzumab) and Leukine(R) (sargramostim) will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH) from December 6-9, 2008 in San Francisco, Californi...
GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
Will Highlight Research Conducted in GenVec Malaria Vaccine Program
GAITHERSBURG, Md., Dec. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) announced today that the company will present on GenVec's malaria vaccine program at the American Societ...
Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola
Pharmaceuticals, a biopharmaceutical company developing innovative drugs
that provide significant advances in cardiovascular and inflammatory
diseases, and cancer, today announced that data relevant to betrixaban, the
company's novel ...
VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
SAN FRANCISCO, Nov. 6 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals,
Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of
compounds for the treatment of cardiovascular disease, announced today that
it will hold a conference call and webcast to discuss results of the
Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
TR-701 Phase 1 Clinical Trial Results Disclosed
SAN DIEGO, Oct. 20 /PRNewswire/ -- Trius Therapeutics, Inc., a
biopharmaceutical company developing "Best-in-Class" drugs for the
treatment of serious bacterial infections, announced today that the results
of multiple studies on its lead progra...
Cytopia Scientific Presentations on JAK2 Inhibitor Program
MELBOURNE, Australia, Oct. 16 /PRNewswire/ -- Cytopia Limited (ASX:
CYT) will present data on its JAK2 inhibitor program at two important
scientific meetings this month.
Dr Emmanuelle Fantino, Head of Biology at Cytopia, will present a
lecture entitled Targeted JAK2 Inhibitors for Myeloproli...
Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
Updated Survival Data for Ipilimumab to be Presented
PRINCETON, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX ) announced today that nine clinical abstracts for ipilimumab,
an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be
the subject of ...
Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.
("Rib-X" or the "Company"), a development-stage company focused on the
discovery and development of novel antibiotics for the treatment of
antibiotic-resistant infections, announced today that company
representatives are givi...
Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
SEATTLE, May 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) today announced that the following presentations
will be made on its product Zevalin(R) (Ibritumomab Tiuxetan) and its
development product OPAXIO(TM) (paclitaxel poliglumex, formerly XYOTAX(TM))
Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
SOUTH EASTON, Mass., May 21 /PRNewswire-FirstCall/ -- Pressure
BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today announced that scientists
from the New York University (NYU) School of Medicine, the Brooklyn
Hospital Center, and the Harvard School of Public Health made presentations
Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
ST. LOUIS, May 20 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq:
STXS) today reported on the favorable endorsements of its Niobe(R) Magnetic
Navigation System and Odyssey(TM) information management tools received
from key opinion leaders in electrophysiology at Heart Rhythm 2008, the
BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
- First in human clinical data highlight safety profile of BSI-201 in subjects with advanced solid tumors -
BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a
privately held biopharmaceutical company developing novel cancer therapies,
today announced that data su...
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
KENILWORTH, N.J., May 15 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ), a leader in advancing the science and treatment of
chronic hepatitis C virus (HCV) infection, announced today that data from
several clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and
Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
Randomized TRIAS HR Pilot Study Compares Genous, Boston Scientific's Taxus(R)
Focus on Real-World Use of Genous, Stent's Performance in Patients with AMI, Those Who Could Not Tolerate Dual-Antiplatelet Therapy
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- Kosan Biosciences
Incorporated (Nasdaq: KOSN ) today announced that updated data will be
presented on tanespimycin, the company's lead Hsp90 inhibitor, from a Phase
2 trial in combination with Herceptin(R) in patients with HER2-positive
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX ) announced today that the following clinical and preclinical
abstracts for ipilimumab in melanoma, prostate cancer and other cancers, as
well as for anti-PD-1 and anti-CD70 antibody candidates for cancer
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
KENILWORTH, N.J., April 17 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ), a leader in advancing the science and treatment of
chronic hepatitis C virus (HCV) infection, announced today that final
results of the IDEAL study as well as from several other clinical studies
Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
SAN DIEGO and SUNNYVALE, Calif., April 15 /PRNewswire-FirstCall/ --
Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced preclinical data from
at the Annual Meeting of the American Association for
Cancer Research (AACR) being held this week in San Diego, CA. Results from
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced that multiple abstracts have
Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Pharmasset, Inc.
(Nasdaq: VRUS ) announces that interim results of physician-sponsored
studies of clevudine for the treatment of chronic hepatitis B virus (HBV)
and both preclinical and clinical results of R7128 for the treatment of
TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
SAN DIEGO, Dec. 6 /PRNewswire/ -- TargeGen, Inc. today announced that
the Company's recently submitted IND for TG101348 is now active and the
Company plans to initiate a multi-center clinical trial of TG101348, an
internally discovered, oral, potent, and highly selective JAK2 inhibitor in
CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
BRANFORD, Conn., Nov. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on
oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced
today that updated preliminary clinical trial results from the Phase II
Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Leading researchers
will present 68 data presentations
involving Schering-Plough's hepatitis
products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R)
(ribavirin, USP) combination therapy, a current standard of care in the
Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
DALLAS, Oct. 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.
(OTC Bulletin Board: ACCP) announced today that two posters describing
significant preclinical studies performed by Access collaborators at two
prominent institutes in France, were presented last week at the joint
Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
REDWOOD CITY, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Threshold
Pharmaceuticals, Inc. (Nasdaq: THLD ), will host a conference call today at
4:30 p.m. ET to discuss the Phase 2 and Phase 3 presentations
made at the ECCO proceedings last week. Joining the Company on the conference c...
Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
Detailed Data from the Phase 3 Glufosfamide and Phase 2 Glufosfamide Plus Gemcitabine Clinical Trials to be Presented
REDWOOD CITY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Threshold
Pharmaceuticals, Inc. (Nasdaq: THLD ), today announced two presentations
regarding its oncology p...
Oridion Announces Major Medical Research and Congress Presentations
JERUSALEM and NEEDHAM, Massachusetts, June 17 /PRNewswire-FirstCall/ --
Oridion Systems Ltd. - (SWX: ORIDN) Significant findings from numerous
medical research projects demonstrating the clinical benefit of end-tidal
CO2 (EtCO2) monitoring using Microstream(R) capnography technology, were
IDM Pharma Announces Upcoming Clinical Data Presentations
IRVINE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI ), a biotechnology company focused on the development of
innovative cancer therapies, today announced details on clinical data
presentations evaluating three of the Company's pipeline compounds to be
Accentia Biopharmaceuticals Scientific Presentations Demonstrate
Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at
the Annual Meeting of the American Academy of Allergy, Asthma, and
TAMPA, Fla.--(BUSINESS WIRE)--Mar 7, 2007 - Accentia
Biopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters at
the Annual Meeting of the American Academy of Allergy, Asthma, and
Immunology from February 23 - 27, 2007 in San Diego, CA. The
posters discussed findings from a survey of 202 ot...
Pharmasset Announces Clevudine and Hepatitis C Presentations at
The 42nd Annual Meeting of the European Association for the Study
of the Liver
PRINCETON, N.J., April 03, 2007 /PRNewswire/ -- Pharmasset
announced today that presentations
of preclinical studies of
Clevudine for the treatment of hepatitis B (HBV) and PSI-6130, the
parent molecule of R7128, for th...